GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » DA32 Life Science Tech Acquisition Corp (NAS:DALS) » Definitions » Return-on-Tangible-Asset

DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Return-on-Tangible-Asset : 1.62% (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DA32 Life Science Tech Acquisition Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DA32 Life Science Tech Acquisition's annualized Net Income for the quarter that ended in Mar. 2023 was $3.30 Mil. DA32 Life Science Tech Acquisition's average total tangible assets for the quarter that ended in Mar. 2023 was $204.42 Mil. Therefore, DA32 Life Science Tech Acquisition's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2023 was 1.62%.

The historical rank and industry rank for DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset or its related term are showing as below:

DALS' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.29   Med: 0.29   Max: 0.85
Current: 0.85

During the past 2 years, DA32 Life Science Tech Acquisition's highest Return-on-Tangible-Asset was 0.85%. The lowest was 0.29%. And the median was 0.29%.

DALS's Return-on-Tangible-Asset is not ranked
in the Diversified Financial Services industry.
Industry Median: -0.84 vs DALS: 0.85

DA32 Life Science Tech Acquisition Return-on-Tangible-Asset Historical Data

The historical data trend for DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DA32 Life Science Tech Acquisition Return-on-Tangible-Asset Chart

DA32 Life Science Tech Acquisition Annual Data
Trend Dec21 Dec22
Return-on-Tangible-Asset
- 0.29

DA32 Life Science Tech Acquisition Quarterly Data
Apr21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Return-on-Tangible-Asset Get a 7-Day Free Trial -0.60 -0.92 0.76 1.94 1.62

Competitive Comparison of DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset

For the Shell Companies subindustry, DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset falls into.



DA32 Life Science Tech Acquisition Return-on-Tangible-Asset Calculation

DA32 Life Science Tech Acquisition's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=0.599/( (202.493+203.856)/ 2 )
=0.599/203.1745
=0.29 %

DA32 Life Science Tech Acquisition's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=3.304/( (203.856+204.984)/ 2 )
=3.304/204.42
=1.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2023) net income data.


DA32 Life Science Tech Acquisition  (NAS:DALS) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


DA32 Life Science Tech Acquisition Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of DA32 Life Science Tech Acquisition's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
345 Park Avenue South, 12th Floor, New York, NY, USA, 10010
Website
DA32 Life Science Tech Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Executives
Da32 Sponsor Llc 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Management Company, L.p. (series C) director, 10 percent owner, other: Director by deputization 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Fund Xi, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Section 32 Fund 3, Lp 10 percent owner, other: Director by Deputization 169 UNIVERSITY AVE., PALO ALTO CA 94301
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
William J Maris 10 percent owner, other: Director by Deputization 2033 SAN ELIJO AVE., #565, CARDIFF-BY-THE-SEA CA 92007
Angela Lai director 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Partners Xi, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xi, L.p. 10 percent owner 8755 W HIGGINS RD., SUITE 1025, CHICAGO IL 60631
Section 32 Gp 3, Llc 10 percent owner, other: Director by Deputization 171 MAIN STREET, #671, LOS ALTOS CA 94022
Steven J. Kafka director, officer: Chief Executive Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Andrew Elbardissi director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Chris Wolfe officer: Chief Financial Officer 230 PARK AVENUE SOUTH, 11TH FLOOR, C/O CAPITAL Z PARTNERS, NEW YORK NY 10003
Kristina Burow 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718